Skip to content
Catalyst

PapersPMID:15495101

Arginine supplementation for prevention of necrotising enterocolitis in preterm infants.

The Cochrane database of systematic reviews2004The record ↗

  1. Finding, very limited evidencelowersNecrotising enterocolitis incidence

What moved

1 findingHow to read these marks →
  • Decreases necrotising enterocolitis incidence

    very limitedreplicated ×2

    “There was a statistically significant reduction in the risk of developing NEC (any stage) in the arginine group compared with the placebo group (RR 0.24 [95% CI 0.10, 0.61], RD -0.21 [95% CI -0.32, -0.09]).”
    Study
    meta-analysis
    Effect
    0.24 risk ratio, 95% CI 0.1 to 0.61
    Population
    preterm neonates given enteral or parenteral arginine supplementation vs placebo or no treatment, pooled from the single eligible trial identified by this review

Study record

Design
meta-analysis / systematic review, not pooled
Species
human
Population
preterm neonates given enteral or parenteral arginine supplementation for at least 7 days vs placebo or no treatment
Participants
not reported
Comparator
not stated in the paper / placebo
Duration
not reported
Endpoints measured
2